AIHTA - Publications - Search - Trabectedin (Yondelis ®) for second-line recurrent platinum-sensitive ovarian cancer

Hintringer, K. (2010): Trabectedin (Yondelis ®) for second-line recurrent platinum-sensitive ovarian cancer. DSD: Horizon Scanning in Oncology 07.

[thumbnail of DSD_HSO_Nr.07.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Due to different modes of action the addition of trabectedin to pegylated liposomal doxorubicin (PLD), this regimen is assumed to benefit relapsed platinum-sensitive ovarian cancer patients. Phase III study results show a moderate improvement regarding the surrogate PFS of 1.7 months when trabectedin is added to PLD compared to the PLD arm alone. Hence, both, FDA and EMEA call for mature OS data to support the prolonged surrogate PFS. Further, due to lack of head-to-head trials with other available therapy options the relative efficacy of these regimens has to be determined.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:ovarian cancer, OC, trabectedin, Yondelis, oncology
Subjects:WP Gynaecology > WP 440-468 Uterine diseases
QZ Pathology > QZ 200-380 Neoplasms.Cysts
Series Name:DSD: Horizon Scanning in Oncology 07
Deposited on:28 Jan 2010 19:43
Last Modified:15 Jul 2020 17:43

Repository Staff Only: item control page